Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423044 | 1.00 | CYP2D6 (0.45) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL5214251 | 0.93 | PAX8 (0.38) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL5209066 | 0.82 | CYP2D6 (0.49) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4803556 | 0.78 | CYP3A4 (0.52) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL6999285 | 0.77 | CYP3A4 (0.48) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL7122981 | 0.76 | CYP3A4 (0.52) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| Trifluoroacetic Acid SCHEMBL4809424 | 0.76 | CYP3A4 (0.47) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| Trifluoroacetic Acid SCHEMBL4807315 | 0.76 | CYP3A4 (0.47) | CYP2D6NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL219603 | 0.75 | SMN1; SMN2 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL6992189 | 0.74 | CYP2D6 (0.47) | CYP2D6NPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381734-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | disclosed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20050267173-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-12-01 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1343561-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-1294691-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-03-26 | — | — | EP | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096305-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | CYP2D6 786/4885NPC1 3113/4885RAB9A 2685/4885 |
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | CYP2D6 1520/4885NPC1 920/4885RAB9A 3346/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | CYP2D6 477/4885NPC1 1831/4885RAB9A 2314/4885 |
| US-20050267173-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | CYP2D6 786/4885NPC1 3113/4885RAB9A 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.